Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis

Objective: After Gemstone-302 was published in Lancet in January 2022, seven PD-(L)1 inhibitors launched or about to be launched in China, but there are no head-to-head RCTs reporting the comparative efficacy for squamous non-small cell lung cancer (sq-NSCLC). Therefore, we aimed to indirectly compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Mingye, Shao, Taihang, Ren, Yinan, Zhou, Caicun, Tang, Wenxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558711/
https://www.ncbi.nlm.nih.gov/pubmed/36249794
http://dx.doi.org/10.3389/fphar.2022.910656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558711/
https://www.ncbi.nlm.nih.gov/pubmed/36249794
http://dx.doi.org/10.3389/fphar.2022.910656

Ejemplares similares